USA, San Diego-based Genome Insight has raised $23 million in Series B-2 funding to further its mission of bringing whole-genome-based precision diagnostics to routine clinical care. Led by Samsung Venture Investment Corporation, Asan Foundation, SCL Group, and Ignite Innovation, the round also saw participation from existing investors. Genome Insight, led by Founder and CEO Young Seok Ju, focuses on utilizing whole-genome technology for accurate diagnosis and personalized treatment in cancer and rare diseases. The funding will support the company's efforts to enhance its CancerVision test, which provides precise, timely, and medically relevant information for individualized healthcare decisions in cancer by analyzing whole-genome mutational profiles.